Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas

Prior evidence has implicated leucocyte expansion in several cardiovascular disorders, including heart failure (HF) with reduced ejection fraction (rEF). However, the prognostic importance of leucocyte count in HF with preserved EF (HFpEF) remains largely unexplored.

[1]  D. Mann,et al.  Reappraising the role of inflammation in heart failure , 2020, Nature Reviews Cardiology.

[2]  Tyler J. VanderWeele,et al.  Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies , 2019, JAMA.

[3]  S. Prabhu,et al.  Dysfunctional and Proinflammatory Regulatory T-Lymphocytes Are Essential for Adverse Cardiac Remodeling in Ischemic Cardiomyopathy , 2019, Circulation.

[4]  Akshay S. Desai,et al.  The frailty syndrome and outcomes in the TOPCAT trial , 2018, European journal of heart failure.

[5]  R. Carter,et al.  A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction , 2018, Circulation.

[6]  C. Reid,et al.  Risk factors for incident heart failure with preserved or reduced ejection fraction, and valvular heart failure, in a community-based cohort , 2018, Open Heart.

[7]  Sumanth D. Prabhu,et al.  CCR2+ Monocyte-Derived Infiltrating Macrophages Are Required for Adverse Cardiac Remodeling During Pressure Overload , 2018, JACC. Basic to translational science.

[8]  N. Houstis,et al.  Cardiac macrophages promote diastolic dysfunction , 2018, The Journal of experimental medicine.

[9]  Wen-Chung Yu,et al.  Hemographic indices are associated with mortality in acute heart failure , 2017, Scientific Reports.

[10]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[11]  M. Entman,et al.  Dissecting the role of myeloid and mesenchymal fibroblasts in age-dependent cardiac fibrosis , 2017, Basic Research in Cardiology.

[12]  Akshay S. Desai,et al.  Spironolactone Metabolites in TOPCAT - New Insights into Regional Variation. , 2017, The New England journal of medicine.

[13]  A. Hingorani,et al.  Neutrophil Counts and Initial Presentation of 12 Cardiovascular Diseases , 2017, Journal of the American College of Cardiology.

[14]  S. Prabhu,et al.  Activated T Lymphocytes are Essential Drivers of Pathological Remodeling in Ischemic Heart Failure , 2017, Circulation. Heart failure.

[15]  M. Redfield.  Heart Failure with Preserved Ejection Fraction. , 2016, The New England journal of medicine.

[16]  Daniel G. Anderson,et al.  Proliferation and Recruitment Contribute to Myocardial Macrophage Expansion in Chronic Heart Failure. , 2016, Circulation research.

[17]  D. Kass,et al.  Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap , 2016, Circulation.

[18]  S. Prabhu,et al.  The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. , 2016, Circulation research.

[19]  Rahul Rattan,et al.  Monocyte Subsets and Inflammatory Cytokines in Acute Decompensated Heart Failure. , 2016, Journal of cardiac failure.

[20]  C. Woolthuis,et al.  Hematopoietic stem/progenitor cell commitment to the megakaryocyte lineage. , 2016, Blood.

[21]  Jason P. Fine,et al.  Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks , 2022 .

[22]  R. Karas,et al.  Left Ventricular T-Cell Recruitment Contributes to the Pathogenesis of Heart Failure , 2015, Circulation. Heart failure.

[23]  V. V. Empel,et al.  Inflammation in HFpEF: Key or circumstantial? , 2015 .

[24]  W. Edwards,et al.  Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction , 2015, Circulation.

[25]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[26]  V. V. van Empel,et al.  Inflammation in HFpEF: Key or circumstantial? , 2015, International journal of cardiology.

[27]  Lesley M. Chapman,et al.  Emerging roles for platelets as immune and inflammatory cells. , 2014, Blood.

[28]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[29]  S. Prabhu,et al.  Integrative Physiology Methods and Results: We Evaluated C57bl/6 Mice with Chronic Hf 8 Weeks after Coronary Ligation. as Compared with Sham-operated Controls, Hf Mice Exhibited: (1) Increased Proinflammatory Cd11b , 2022 .

[30]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[31]  E. Wong,et al.  Why does my patient have thrombocytopenia? , 2012, Hematology/oncology clinics of North America.

[32]  Akshay S. Desai,et al.  Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. , 2011, American heart journal.

[33]  D. Fairlie,et al.  Inhibition of Inflammation and Fibrosis by a Complement C5a Receptor Antagonist in DOCA-Salt Hypertensive Rats , 2011, Journal of cardiovascular pharmacology.

[34]  Antony Vinh,et al.  Inflammation, Immunity, and Hypertension , 2011, Hypertension.

[35]  P. Steendijk,et al.  Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction , 2011, Circulation. Heart failure.

[36]  E. Ravussin,et al.  The NALP3/NLRP3 Inflammasome Instigates Obesity-Induced Autoinflammation and Insulin Resistance , 2010, Nature Medicine.

[37]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[38]  O. Melander,et al.  Leukocyte Count and Incidence of Hospitalizations Due to Heart Failure , 2009, Circulation. Heart failure.

[39]  K. Ley,et al.  Homeostatic Regulation of Blood Neutrophil Counts , 2008, The Journal of Immunology.

[40]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[41]  G. Hansson.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[42]  M. Domanski,et al.  White blood cell count and mortality in patients with ischemic and nonischemic left ventricular systolic dysfunction (an analysis of the Studies Of Left Ventricular Dysfunction [SOLVD]) , 1999, The American journal of cardiology.

[43]  C. Abildgaard,et al.  Thrombopoiesis. , 2020, Seminars in hematology.